Role of tumor microenvironment in cancer progression and therapeutic strategy
Cancer Medicine · 2023-05 · 12 (10) · 11149-11165
DOI: 10.1002/cam4.5698 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 21.02.2023. Verfasst von Qingjing Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Neoplasms. Die Arbeit wurde bisher 464-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer is now considered a tumor microenvironment (TME) disease, although it was originally thought to be a cell and gene expression disorder. Over the past 20 years, significant advances have been made in understanding the complexity of the TME and its impact on responses to various anticancer therapies, including immunotherapies. Cancer immunotherapy can recognize and kill cancer cells by regulating the body's immune system. It has achieved good therapeutic effects in various solid tumors and hematological malignancies. Recently, blocking of programmed death‐1 (PD‐1), programmed death‐1 ligand‐1 (PD‐L1), and programmed death Ligand‐2 (PD‐L2), the construction of antigen chimeric T cells (CAR‐T) and tumor vaccines have become popular immunotherapies Tumorigenesis, progression, and metastasis are closely related to TME. Therefore, we review the characteristics of various cells and molecules in the TME, the interaction between PD‐1 and TME, and promising cancer immunotherapy therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
- Institute of Pharmaceutical Biotechnology & Research Center for Clinical Pharmacy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- The EnMed Program at Houston Methodist Hospital, Texas A&M University College of Medicine and College of Engineering, Houston, Texas, USA.
ORCID-Profile: Yuxuan Zhang, Hangping Yao, Keda Chen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Q., Shao, X., Zhang, Y., Zhu, M., Wang, F. X. C., Mu, J., Li, J., Yao, H., & Chen, K. (2023). Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Medicine, 12(10), 11149-11165. https://doi.org/10.1002/cam4.5698
Vancouver
Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Medicine. 2023;12(10):11149-11165. doi:10.1002/cam4.5698
BibTeX
@article{Wang2023,
author = {Wang, Qingjing and Shao, Xueting and Zhang, Yuxuan and Zhu, Miaojin and Wang, Frederick X C and Mu, Jianjian and Li, Jiaxuan and Yao, Hangping and Chen, Keda},
title = {Role of tumor microenvironment in cancer progression and therapeutic strategy},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {10},
pages = {11149--11165},
doi = {10.1002/cam4.5698}
}
EUVIMED